Atorvastatin May Attenuate Recurrence of Chronic Subdural Hematoma
Hua Liu1, Zhengxiang Luo2, Zhongkun Liu3
1Department of Neurosurgery, The First People's Hospital of Kunshan Affiliated with Jiangsu University Suzhou, China.
Insights
Atorvastatin significantly reduced the recurrence of chronic subdural hematoma (CSDH) after surgery. Severe brain atrophy and bilateral hematoma were identified as key risk factors for CSDH recurrence.
Area of Science:
- Neurosurgery
- Pharmacology
Background:
- Chronic subdural hematoma (CSDH) presents a significant clinical challenge due to its high recurrence rate after surgical intervention.
- The potential of atorvastatin, known for anti-inflammatory and pro-angiogenesis properties, in preventing CSDH recurrence remains unexplored.
Purpose of the Study:
- To evaluate the efficacy of atorvastatin in reducing the recurrence of CSDH post-surgery.
- To identify factors predictive of hematoma recurrence in patients undergoing CSDH surgery.
Main Methods:
- A prospective study involving 168 surgical CSDH cases was conducted.
- Patients were randomized into atorvastatin and control groups, with subsequent comparison of clinical data and recurrence rates.
- Logistic regression analysis was employed to assess the relationship between atorvastatin treatment, brain atrophy, and hematoma characteristics (septated, bilateral) and recurrence.
Main Results:
- The atorvastatin group demonstrated a significantly lower recurrence rate (P=0.023) and a longer time-to-recurrence (P=0.038).
- Admission brain atrophy and bilateral hematoma were significantly associated with recurrence (P=0.047 and P=0.045, respectively).
- Logistic regression confirmed atorvastatin's significant reduction in recurrence probability, identifying severe brain atrophy and bilateral hematoma as independent risk factors.
Conclusions:
- Atorvastatin administration appears to be effective in decreasing the risk of chronic subdural hematoma recurrence.
- Patients presenting with severe brain atrophy and bilateral CSDH are more susceptible to recurrence.
Objective:
Chronic subdural hematoma (CSDH) is a common form of intracranial hemorrhage with a substantial recurrence rate. Atorvastatin may reduce CSDH via its anti-inflammatory and pro-angiogenesis effects, but its effectiveness for preventing recurrent CSDH has never been explored. We hypothesized that atorvastatin is effective in reducing recurrence of CSDH after surgery and identified determining factors predictive of hematoma recurrence.
Methods:
A prospective study was conducted in 168 surgical cases of CSDH.All patients were randomly assigned to the group treated with atorvastatin or control group. Clinically relevant data were compared between two groups, and subsequently between the recurrence and non-recurrence patients. Multiple logistic regression analysis of the relationship between atorvastatin treatment and the recurrence using brain atrophy, septated and bilateral hematoma was performed.
Results:
Atorvastatin group conferred an advantage by significantly decreasing the recurrence rate (P = 0.023), and patients managed with atorvastatin also had a longer time-to-recurrence (P = 0.038). Admission brain atrophy and bilateral hematoma differed significantly between the recurrence and non-recurrence patients (P = 0.047 and P = 0.045). The results of logistic regression analysis showed that atorvastatin significantly reduced the probability of recurrence; severe brain atrophy and bilateral hematoma were independent risk factors for recurrent CSDH.
Conclusions:
Atorvastatin administration may decrease the risks of recurrence.Patients with severe brain atrophy and bilateral CSDH are prone to the recurrence.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins